Fresenius Kabi Pharma Portugal

Fresenius Kabi Pharma Portugal is identified in the supplied evidence as a company in Carnaxide, Portugal, and is represented online by Fresenius Kabi’s Portuguese-language website. The available material does not specify the company’s founding date, legal structure, ownership arrangement, leadership, or the precise boundaries of its Portuguese operations. The Portuguese site presents Fresenius Kabi as a healthcare business specializing in medicines and technologies for people with critical and chronic illnesses. Its stated areas include essential medicines and technologies for infusion, transfusion, and clinical nutrition. The company describes its work in terms of supporting patients and caregivers and contributing to access to reliable, high-quality healthcare. The site also presents sustainability and responsible, ethical management as part of its approach. The website refers to the group’s “Vision 2026,” describing an ambition to improve the efficiency of therapies and patient treatment and to broaden access to high-quality healthcare. This is presented as a Fresenius Kabi vision, not as a separately documented Portugal-only initiative. The supplied sources do not provide specific Portuguese product names, sales figures, executives, or recent corporate transactions.

The supplied evidence establishes Fresenius Kabi Pharma Portugal as a company in Carnaxide, Portugal, but does not provide a founding date or a detailed account of its establishment and development. Its current Portuguese-language website presents it within the Fresenius Kabi identity and describes the business through its focus on medicines and technologies for patients with critical and chronic conditions. The company’s described areas of work include medicines and technologies for infusion, transfusion, and clinical nutrition. The website frames these offerings as contributing to the accessibility and reliability of healthcare and to the needs of both patients and caregivers. It also highlights a commitment to responsible and ethical management and to improving sustainability performance. The Portuguese website refers to Fresenius Kabi’s “Vision 2026,” an ambition to improve the efficiency of therapies and patient treatment and to improve access to high-quality healthcare worldwide. The available source describes this as a broader Fresenius Kabi vision; it does not document a distinct Portugal-specific launch or milestone. No founding, ownership, leadership, acquisition, listing, or product-launch dates for the Portuguese company are supplied, so these details are left unspecified.

• Fresenius Kabi Vision 2026 referenced on the Portuguese website

Healthcare provider focused on medicines and technologies for critical and chronic patients, including infusion, transfusion, and clinical nutrition.

• Medicines and technologies for infusion, transfusion, and clinical nutrition

  The company describes these as essential offerings for patients with critical and chronic conditions.

1. 1Fresenius Kabi Portugalfresenius-kabi.com
2. 2Uma Empresa com um Compromissofresenius-kabi.com
3. 3Fresenius Kabi Pharma Portugal (Portugal)wikidata.org